...
首页> 外文期刊>Journal of Hepatocellular Carcinoma >Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
【24h】

Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel

机译:用临床加载P(N-异丙基 - 丙烯酰胺 - 丙烯酸甲酯)温度敏感纳米凝胶治疗HCC栓塞后栓塞肿瘤血管生成的效果

获取原文
           

摘要

Background:Transcatheter arterial embolization (TAE) is widely used in hepatocellular carcinoma (HCC) therapy. Tumor hypoxia often correlates with the recurrence and metastasis of the tumor and is the critical factor limiting the treatment effect of TAE.Purpose:To investigate the underlying mechanism and therapeutic potential of TAE combined with apatinib-loaded p(N-isopropyl-acrylamide-co-butyl methyl acrylate) temperature-sensitive (PIB) nanogel for the suppression of rabbit VX2 liver tumor growth.Materials and Methods:Sixty-five VX2 tumor-burdened rabbits were randomly divided into five groups and treated transarterially with apatinib-loaded PIB (Group PA, 0.4 mL, n=13), PIB alone (Group P, 0.4 mL, n=13), iodized oil alone (Group I, 0.4 mL, n=13), apatinib solution (Group A, 0.4 mL, n=13) or saline (Group NS, 0.4 mL, n=13). The dose of apatinib was 2 mg/kg. Tumors were harvested, sectioned and immunohistochemically stained, and the tumor growth rates and survival times in each group were measured. Blood samples and liver tissues were collected for pharmacokinetic analysis.Results:The tumor growth rate in Group PA was considerably lower than the other four groups (P=0.0000.01), and the survival time was significantly prolonged (P=0.0000.01). The immunohistochemistry results showed that CD31 expression was significantly lower in Group PA than that of the other four groups (P=0.0000.01). The apatinib concentration in the blood fell below 10 ng/mL within 10 min after TAE and dropped below 1 ng/mL after 8 h. The drug was released continuously in the liver for 36 days, with the highest concentration at the tumor junction (P=0.0450.05).Conclusion:PIB effectively targeted apatinib to HCC tissues, achieved a slow and sustained release of the drug in the tumor and considerably reduced the systemic drug concentration. Further experiments showed significantly prolonged survival times and an inhibitory effect on tumor growth.? 2020 Zhou et al.
机译:背景:经导管动脉栓塞(TAE)广泛用于肝细胞癌(HCC)治疗。肿瘤缺氧通常与肿瘤的复发和转移相关,并且是限制Tae的治疗效果的关键因素。探讨Tae的潜在机制和治疗潜力与磷含量加载的p(n-异丙基 - 丙烯酰胺-co - 甲基丙烯酸甲酯)温度敏感(PIB)纳米凝胶用于抑制兔VX2肝肿瘤生长。材料和方法:将六十五的Vx2肿瘤荷兰兔随机分为五组,并用磷酸加载的PIB晶莹剔透(组Pa,0.4ml,n = 13),单独的Pib(P组,0.4ml,n = 13),单独碘化油(基团I,0.4ml,n = 13),apatinib溶液(A组,0.4ml,n = 13)或盐水(NS组,0.4ml,n = 13)。 Apatinib的剂量为2mg / kg。收获肿瘤,切片和免疫组织化学染色,测量每组中的肿瘤生长速率和存活时间。收集血液样品和肝组织进行药代动力学分析。结果:PA组中的肿瘤生长速率大得多低于其他四组(P = 0.000 <0.01),存活时间明显延长(P = 0.000 <0.01) 。免疫组织化学结果表明,PA群中CD31表达明显低于其他四组(P = 0.000 <0.01)。血液中的apatinib浓度在TAE后10分钟内下降到10ng / mL以下,并且在8小时后滴加低于1ng / mL。该药物在肝脏中连续释放36天,肿瘤结的最高浓度(P = 0.045 <0.05)。结论:PIB有效地靶向HCC组织,在肿瘤中达到了慢慢释放的药物并且大大降低了系统性药物浓度。进一步的实验显示出显着的存活时间和对肿瘤生长的抑制作用。 2020周等人。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号